In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL

Drug Delivery

Volumn 16, Issue 1, 2009, Pages 45-51

  Skidan, Igor ^a   Miao, Benchun ^b   Thekkedath, Ritesh V ^a   Dholakia, Parita ^a   Degterev, Alexei ^b   Torchilin, Vladimir ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

TRAIL resistant cancer cells

Indexed keywords

ANTINEOPLASTIC AGENT; MACROGOL 2000; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C5; N [[[2 HYDROXY 5 NITROPHENYL)AMINO]CARBONOTHIOYL] 3,5 DIMETHYLBENZAMIDE; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIOLEOYL N (MONOMETHOXYPOLYETHYLENE GLYCOL SUCCINYL)PHOSPHATIDYLETHANOLAMINE; DIOLEOYL-N-(MONOMETHOXYPOLYETHYLENE GLYCOL SUCCINYL)PHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; MACROGOL DERIVATIVE; N (((2 HYDROXY 5 NITROPHENYL)AMINO)CARBONOTHIOYL) 3,5 DIMETHYLBENZAMIDE; N-(((2-HYDROXY-5-NITROPHENYL)AMINO)CARBONOTHIOYL)-3,5-DIMETHYLBENZAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CELL STRAIN MCF 7; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MICELLE; NONHUMAN; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MOUSE; NEOPLASM; SOLUBILITY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; MICELLES; NANOPARTICLES; NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; PHOSPHATIDYLINOSITOL PHOSPHATES; POLYETHYLENE GLYCOLS; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 70349566804     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540802517951     Document Type: Article

References (32)

1. Ballestrero A, Montemurro F, Gonella R, Capaldi A, Danova M, Friedman D, Puglisi M, Aglietta M, Patrone F (2003). Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: Anti- tumor activity and peripheral blood progenitor cell mobilization capability. Breast Cancer Res Treat. 82, 185-190.
2. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/ TRAIL-induced apoptosis. Cell Death Differ. 11, 915-923.
3. Elbayoumi TA, Pabba S, Roby A, Torchilin VP (2007). Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor- targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 17, 1-14.
4. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598.
5. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O'Bryan E, Fumero C, Wang HG, Bhalla K (2002). Ectopic overexpression of second mitochondria- derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative- (BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99, 3419-3426.
6. Iakoubov LZ, Torchilin VP (1997). A novel class of antitumor antibodies: Nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 9, 439-446.
7. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564-567.
8. Kawakami K, Oda N, Miyoshi K, Funaki T, Ida Y (2006). Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 28, 7-14.
9. Kelley SK, Ashkenazi A (2004). Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333-339.
10. Kwon GS, Naito M, Yokoyama M, Okano T, Sakurai Y, Kataoka K (1995). Physical entrapment of adriamycin in AB block copolymer micelles. Pharm. Res. 12, 192-195.
11. Lee H, Hu M, Reilly RM, Allen C (2007). Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Mol. Pharm. 4, 769-781.
12. Lukyanov AN, Gao Z, Mazzola L, Torchilin V (2002). Polyethylene glycol- diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm. Res. 19, 1424-1429
13. Maeda H (2001). The enhanced permeability retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207.
14. Mallick S, Pattnaik S, Swain K, De PK (2007). Current perspectives of solubilization: Potential for improved bioavailability. Drug Dev. Ind. Pharm. 33, 865-873.
15. Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP (1985). Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: Correlation with its hypotensive action in the dog Agents Actions 16, 470-477.
16. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997)a. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818.
17. Pan G, O'Rourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J, Dixit VM (1997)b. The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113.
18. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R, Gu J, Qian C, Liu X (2004). An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39, 1371-1381.
19. Rajebahadur M, Zia H, Nues A, Lee C (2006). Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15. Drug Deliv. 13, 201-206.
20. Roby A, Erdogan S, Torchilin V (2006). Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur. J. Pharm. Biopharm. 62, 235-240.
21. Safavy A, Raisch K, Mantena S, Sanford L, Sham S, Krishna N, Bonner J (2007). Design and development of water-soluble curcumin conjugates as potential anticancer agents. 50, 6284-6288.
22. Scripture C, Figg WD, Sparreboom A (2005). Paclitaxel chemotherapy: From empiricism to a mechanism-based formulation strategy. Ther. Clin. Risk Manag. 1, 107-114.
23. Sethuraman V, Bae YH (2007). TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Contr. Rel. 118, 216-224.
24. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997). Control of TRAILinduced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821.
25. Skidan I, Degterev A, Torchilin V (2007). Micellar form of novel poorly soluble proapoptotic agent, Dimethyl-PIT. 2007. 34th Annual CRS meeting, Long Beach, CA, July 7-11, 2007, Abstract #247.
26. Skidan I, Dholakia P, Torchilin V (2008)a. Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20- tetraphenylporphin-loaded PEG-PE micelles. J. Drug Target. 16, 486-493.
27. Skidan I, Dholakia P, Degterev A, Torchilin V (2008b). PEG-PE micelles with novel poorly-soluble proapoptotic agent: Activity in vivo. 35th Annual CRS meeting, New York, July 12-16, Abstract #648.
28. Torchilin V (2007). Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24, 1-16.
29. Torchilin V, Levchenko T, Lukyanov A, Khaw B, Klibanov A, Rammohan R, Samokhin G, Whiteman K (2001). p-Nitrophenylcarbonyl-PEG-PE-liposomes: Fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511, 397-411.
30. Torchilin V, Lukyanov A, Gao Z, Papahadjopoulos-Sternberg B (2003). Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. USA 100, 6039-6044.
31. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A (2001). Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47, 309-318. (Pubitemid 32640770)
32. Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 348, 137-145.